Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment. (November 2020)

Record Type:: Journal Article
Title:: Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment. (November 2020)
Main Title:: Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment
Authors:: Robinson, Philip C
Richards, Duncan
Tanner, Helen L
Feldmann, Marc
Abstract:
Is Part Of:: Lancet. Volume 2:Number 11(2020)
Journal:: Lancet
Issue:: Volume 2:Number 11(2020)
Issue Display:: Volume 2, Issue 11 (2020)
Year:: 2020
Volume:: 2
Issue:: 11
Issue Sort Value:: 2020-0002-0011-0000
Page Start:: e653
Page End:: e655
Publication Date:: 2020-11
Subjects:: Rheumatology -- periodicals
616.72305
Journal URLs:: https://www.thelancet.com/journals/lanrhe/issues#decade=loi_decade_201 ↗
https://www.sciencedirect.com/journal/the-lancet-rheumatology ↗
http://www.sciencedirect.com/ ↗
DOI:: 10.1016/S2665-9913(20)30309-X ↗
Languages:: English
ISSNs:: 2665-9913
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:: 14730.xml